date,title,source
Oct-19-18,"Detailed Research: Economic Perspectives on BeiGene, Costco Wholesale, Rogers, Advance Auto Parts, Celcuity, and Harris  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-22-18,BRIEF-Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors,Reuters
Oct-22-18,BeiGene (BGNE): Moving Average Crossover Alert,Zacks
Oct-22-18,BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress,GlobeNewswire
Oct-24-18,BRIEF-Beigene Announces Acceptance Of Its New Drug Application In China,Reuters
Oct-24-18,BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,GlobeNewswire
Nov-01-18,BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting,GlobeNewswire
Nov-01-18,Today's Research Reports on Trending Tickers: Gilead Sciences and BeiGene,ACCESSWIRE
Nov-05-18,BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology,GlobeNewswire
Nov-07-18,BRIEF-Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib,Reuters
Nov-07-18,BeiGene Reports Third Quarter 2018 Financial Results,GlobeNewswire
Nov-07-18,BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,GlobeNewswire
Nov-08-18,Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors,PR Newswire
Nov-13-18,BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Nov-15-18,BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%,Zacks
Nov-15-18,Priority Review Granted to BeiGenes New Drug Applications for Zanubrutinib and Tislelizumab in China,GlobeNewswire
Nov-16-18,BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology,GlobeNewswire
Nov-20-18,BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference,GlobeNewswire
Nov-21-18,Analysts Take Action on Health Care Stocks,GuruFocus.com
